Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

September 30, 2029

Conditions

Heart Failure With Preserved Ejection FractionMyocardial Fibrosis

Interventions

DRUG

Sacubitril-valsartan

Sacubitril-valsartan titrated to maximally targeted dose

DRUG

Valsartan

Valsartan titrated to maximally targeted dose

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER